Can individuals with low antibody responses to conventional antiviral

vaccines acquire adequate antibody by the SARS-CoV-2 mRNA vaccine?

Short title: Responses to the SARS-CoV-2 mRNA vaccine of low responders to

conventional vaccines

Wataru Ogura[1][¶], Kouki Ohtsuka[2][¶][*], Sachiko Matsuura[1], Takahiro Okuyama[1], Satsuki

Matsushima[2], Satoko Ymasaki[2], Hiroyuki Miyagi[1], Kumiko Sekiguchi[1], Hiroaki

Ohnishi[2], Takashi Watanabe[2]

[1] Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo, Japan

[2] Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka,

Tokyo, Japan

* Corresponding author

E-mail: kouki7@ks.kyorin-u.ac.jp (KO)

[¶]These authors contributed equally to this work.

Abstract

Objective

In Japan, healthcare workers (HCWs) are vaccinated against contagious viruses (measles, rubella, chickenpox, mumps, and hepatitis B) to prevent nosocomial infection. However, some do not produce sufficient antibodies after vaccination (low responders). Whether these low responders to conventional vaccines (live attenuated viruses or inactivated viruses) can produce adequate antibodies to mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains to be elucidated.

Methods

We conducted a prospective cohort study of 50 HCWs who received two doses of mRNA BNT162b2 vaccine 3 weeks apart. SARS-CoV-2 anti-spike antibodies were measured 11 times, from before the first BNT162b2 vaccination to 5 months after the second vaccination. The antibody titers of low responders and normal responders were compared. In addition, SARS-CoV-2 neutralizing antibody activity was measured twice in low responders, 1 week to 1 month, and 5 months after the second vaccination.

Results

After vaccination, SARS-CoV-2 anti-spike antibody was detectable in the samples from low and normal responders at each timepoint. The median SARS-CoV-2 anti-spike antibody titer was higher in low responders than in normal responders 1 week after receiving the second dose of BNT162b2 vaccine (3721.0 vs 2251.5, P=0.029). Low responders had SARS-CoV-2 neutralizing antibody activity 1 week to 1 month, and 5 months after the second vaccination, which exceeded the positive threshold 5 months after the second vaccination.

43 **Conclusion**

44   After BNT162b2 vaccination, low responders acquired adequate SARS-CoV-2

45 anti-spike and SARS-CoV-2 neutralizing antibodies to prevent SARS-CoV-2. These

46 results suggest that vaccination with mRNA vaccine against SARS-CoV-2 should also

47 be recommended for low responders to conventional vaccines.

Introduction

50   Coronavirus disease (COVID-19), which is caused by severe acute respiratory

51 syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic [1-4]. In view of

52 the high number of cases of severe illness and death due to COVID-19, vaccination

53 against SARS-CoV-2 infection is crucial.

54   SARS-CoV-2 has an enveloped, single, positive-stranded RNA genome that

55 encodes four major viral structural proteins, namely, the nucleocapsid, spike, envelope,

56 and membrane proteins; the latter three proteins are found in its membrane. The spike

57 protein guides viral entry into host cells by binding to angiotensin-converting enzyme 2

58 (ACE2) receptors, which are widely expressed on epithelial cells and macrophages [5-7]

59 and is thus an ideal target for messenger RNA (mRNA) vaccine development.

60   The BNT162b2 mRNA vaccine (Pfizer–BioNTech) is highly effective at

61 preventing clinically significant COVID-19 [8-10], reducing the incidence of

62 asymptomatic infection and associated infectivity [11,12], and preventing the spread of

63 COVID-19 [9]. The BNT162b2 vaccine was the first SARS-CoV-2 vaccine to be

64 approved in Japan, and priority vaccination of healthcare workers (HCWs) began in

65 February 2021 in order to safeguard the medical delivery system [13].

HCWs also have a high risk of infection with other contagious viruses such as

measles, rubella, chickenpox, mumps, and hepatitis B. Therefore, in Japan, HCWs are

vaccinated against these viruses to prevent nosocomial infections and viral antibody

titers are measured to ensure the presence of protective antibody levels [14]. However,

some individuals do not develop adequate antibody titers against contagious viruses

even after vaccination. Such individuals are called low responders. It is unclear whether

low responders to conventional vaccines can produce adequate SARS-CoV-2 antibodies,

including neutralizing antibodies, after vaccination with the BNT162b2 vaccine to

protect them against SARS-CoV-2 infection. Therefore, in this study we investigated

whether low responders acquired SARS-CoV-2 anti-spike and SARS-CoV-2

neutralizing antibodies after vaccination with the BNT162b2 vaccine.

Materials and methods

Ethics consideration

80   We carried out a prospective cohort study of 50 HCWs. This study was

81   conducted with the approval of the Ethics Committee of Kyorin University School of

82   Medicine (Number R02-041). Informed consent was obtained from all study

83   participants.

Subjects

The study was conducted at Kyorin University Hospital in Tokyo, Japan.

HCWs at the hospital received two doses of BNT162b2 vaccine, 3 weeks apart. The

participants were HCWs at the hospital who agreed to participate in the study and to

periodically donate blood samples before and after vaccination. Those whose antibody

levels were below the standard values for preventing infection after receiving two or

more doses of vaccine against measles, rubella, chickenpox, mumps, or hepatitis B

viruses were classified as low responders.

SARS-CoV-2 anti-spike antibody assay

SARS-CoV-2 anti-spike antibody measurements were performed on serum

obtained from centrifuged peripheral blood using the Elecsys Anti-SARS-CoV-2 S RUO

(Roche Diagnostics International Ltd, Rotkreuz, Switzerland) on a Cobas 6000 (Roche

Diagnostics) analyzer via the double-antigen sandwich enzyme-linked immunoassay

method [15]. Samples were collected before the first dose of BNT162b2 vaccine was

administered; 3 days after the first vaccination; 1, 2, and 3 weeks after the first

vaccination; 1 week after the second vaccination; and 1, 2, 3, 4, and 5 months after the

second vaccination. The measurement range of the antibody assay was 0.4–250, and

samples with an antibody titer of ≥250 U/mL were assayed again after dilution.

SARS-CoV-2 neutralizing antibody assay

Using serum obtained from the peripheral blood of low responders after

vaccination, SARS-CoV-2 neutralizing antibody activity was measured at Osaka

University Microbial Disease Research Association Laboratory. A 50% inhibitory

dilution factor (ID_{50}) using pseudovirus [16] was measured, and ID_{50} values of ≥50 was

considered positive [17]. For the neutralization assay, 60 μL of pseudovirus, which is

equivalent to 2.5×10^6 relative light units (RLU)/mL, was incubated with 60 μL of serial

dilutions of serum samples for 1 h at 37□. After incubation, 100 μL of the mixture was

added to the Vero cells in a 96-well plate. The cells were lysed 24 h post-infection,

luciferase was activated using the Luciferase Assay System (E1501, Promega,

Wisconsin, USA), and RLU were measured using a Synergy LX analyzer (BioTek,

USA). Percent neutralization was calculated using GraphPad Prism 8.0.2 (GraphPad

Software, San Diego, California, USA). Percentages of RLU reduction (inhibition rate)

were calculated as follows: 1 − (RLU of sample sera − pseudovirus only wells) / (RLU

from medium only wells − pseudovirus only wells) × 100%. The titers of neutralizing

sera were calculated as ID_{50}. The transition of neutralizing antibody activity values after

vaccination in low responders was examined 1 week to 1 month and 5 months after

receiving the second dose of BNT162b2 vaccine.

Statistical analysis

Nonparametric continuous data are reported as median and interquartile range

(IQR). The Mann–Whitney U test was performed to assess whether differences between

cohorts were statistically significant. Two-sided *P*-values of <0.05 were considered

statistically significant. The Wilcoxon matched-pairs signed rank test was performed to

assess whether differences in antibody levels within an individual at different time

points were statistically significant. Regarding the comparison of the age composition

(ratio of 20s to 40s and 50s to 60s) and gender between low responders and normal

responders, Fisher's exact test was performed to test the statistical significance. The

Mann–Whitney U test was performed to test for statistically significant differences in

antibody levels between low responders and normal responders 1 week after the second

vaccination. All statistical analyses were performed with EZR (Saitama Medical Center,

Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The

R Foundation for Statistical Computing, Vienna, Austria) [18]. Specifically, EZR is a

modified version of R commander (version 1.54) that has been designed to add

statistical functions frequently used in biostatistics.

Results

The low responders comprised three males (L1, L2, L4) with a negative (titer

<16.0) anti-measles immunoglobulin G (IgG) antibody titer after measles virus

vaccination and one female (L3) with a negative (titer <4.0) anti-mumps IgG antibody

titer after mumps virus vaccination. Forty-six participants, comprising 12 males and 34

females, had antiviral antibody titers after vaccination against other viruses above the

standard value (normal responders). The four low responders were aged 20s to 40s years.

Normal responders were older than low responders (the ratio of aged 50s to 60s years

was 57% vs. 0%, respectively), but no significant difference was observed (P >0.99). In

addition, male/female ratio was higher in low responders than in normal responders

(74% vs. 15%), but no significant difference was observed (P >0.99). All low

responders were non-smokers and non-obese, and none of them had a history of taking

immunosuppressive drugs or having a medical condition associated with

immunodeficiency.

SARS-CoV-2 anti-spike antibody levels

The median (IQR) SARS-CoV-2 anti-spike antibody titer was 2251.5 (1639.0–

3276.3) in the normal responders and 3721.0 (3255.0–4983.3) in the low responders 1

week after receiving the second dose of BNT162b2 vaccine. This difference was

statistically significant (P=0.029) (Fig 1A). In the total antibody level 1 week after the

second vaccination, there was no significant difference in the median antibody levels

between the aged 50s to 60s and 20s to 40s years (P=0.66).

The median (IQR) SARS-CoV-2 anti-spike antibody in normal responders was

2251.5 (1639.0–3276.3) and 779.3 (534.6–1024.3) measured 1 week and 5 months,

respectively, after receiving the second dose of BNT162b2 vaccine (Fig 1B). In low

responders, the median (IQR) SARS-CoV-2 anti-spike antibody was 3721.0 (3255.0–

4983.3) and 666.7 (578.9–880.6) measured 1 week and 5 months, respectively, after

receiving the second dose of BNT162b2 vaccine (Fig 1C).

SARS-CoV-2 anti-spike antibody was produced by both low and normal

responders, but the level was lower at 5 months than at 1 week after the second dose of

vaccine (Fig 1).

Fig 1. SARS-CoV-2 anti-spike antibody responses in low/normal responders before

and after vaccination with the BNT162b2 vaccine

(A) SARS-CoV-2 anti-spike antibody responses over the whole study period from

before the first dose to 5 months after the second dose of vaccine.

(B) SARS-CoV-2 anti-spike antibody titers in normal responders 1 week and 5 months

after receiving the second dose of BNT162b2 vaccine. The antibody titers were

significantly lower at 5 months than at 1 week after the second dose (P<0.001).

(C) SARS-CoV-2 anti-spike antibody titers in low responders 1 week and 5 months after

receiving the second dose of BNT162b2 vaccine. The antibody titers decreased, but the

decrease was not statistically significant (P=0.068).

The box plot comparisons were performed using the Mann–Whitney U test. *P*-values

<0.05 were considered statistically significant. Low responders had low-level antibody

responses to previous measles or mumps vaccines, and normal responders had normal

antibody responses to previous antiviral vaccines.

NaN; not a number

SARS-CoV-2 neutralizing antibody activity in participants

with low-level antibody responses to previous antiviral

vaccines

191   SARS-CoV-2 neutralizing antibody titers were 1154.0 in L1 at 1 week after

receiving the second dose of BNT162b2 vaccine and 774.2, 638.3, and 654.6 in L2, L3,

and L4, respectively, at 1 month after receiving the second dose of BNT162b2 vaccine

(Fig 2). In the 5 months after the second vaccination, SARS-CoV-2 neutralizing

antibody titers were 105.5, 147.7, 485.2, and 894.4 in L1, L2, L3, and L4, respectively

(Fig 2). All four low responders had neutralizing antibody activity within the protective

range (≥50), from the 1 week to 1 month and 5 months after the second vaccination

(Fig 2). The SARS-CoV-2 neutralizing antibody level in low responders was lower at 5

months after receiving the second dose of BNT162b2 vaccine than at 1 week to 1 month

after receiving the second dose, but this difference was not statistically significant

(*P*=0.38) (Fig 2).

Fig 2. SARS-CoV-2 neutralizing antibody activity responses after the second dose

of BNT162b2 vaccine in low responders.

Data are presented as 50% inhibitory dilutions (ID_{50}). The dashed line indicates the

cutoff for ID_{50} [17].

Discussion

The BNT162b2 vaccine has been highly effective in preventing clinically

significant COVID-19 [8-10]. However, limited information is available about the

effectiveness of the BNT162b2 vaccine in low responders to conventional vaccines. In

this study, low responders produced adequate SARS-CoV-2 anti-spike antibodies and

neutralizing antibodies.

Muik et al. [19] measured the neutralization efficacy of sera from 40 healthy

German subjects immunized with the BNT162b2 vaccine and a 50% inhibitory dilution

factor using pseudovirus according to the same method as was used in this study. The

SARS-CoV-2 neutralizing activity of the low responders in this study 1 week to 1

month after receiving the second dose of BNT162b2 vaccine was comparable to that of

the participants in the German study. All four low responders developed protective

levels of neutralizing antibodies. The SARS-CoV-2 neutralizing antibody activity value

in the fifth month after the second dose of BNT162b2 vaccine did not show a significant

decrease in activity compared with that 1 week to 1 month after receiving the second

dose of BNT162b2 vaccine. The SARS-CoV-2 anti-spike antibody titer was lower at 5

months after the second dose of BNT162b2 vaccine than at 1 week after the second

dose, but the decrease was not statistically significant in low responders. These results

suggest that mRNA vaccines can invoke a protective immune response even in low

responders who do not develop adequate antibody titers against viruses in response to

conventional vaccines against viral diseases such as mumps and measles.

Measles, rubella, chickenpox, and mumps vaccines are live attenuated vaccines

that weaken the toxicity of pathogenic microorganisms, and hepatitis B vaccines are

inactivated vaccines that cause pathogenic microorganisms to lose their ability to infect

[20]. In previous studies, approximately 2–10% of healthy individuals do not produce

protective antibody levels in response to viral vaccines [21]. The risk factors for low

response to these conventional viral vaccines include male sex, age of >40s, smoking

habit, obesity, chronic diseases, and genetic factors. However, the factors associated

with a low antibody response to SARS-CoV-2 mRNA vaccines are not well understood.

Smokers, patients with cancer and hematological malignancies, and organ transplant

recipients have been reported to have a lower SARS-CoV-2 anti-spike antibody

response than individuals without these characteristics after receiving SARS-CoV-2

vaccines [22-26]. It is intriguing that the low responders in this study who did not

produce adequate antibody against measles or mumps produced adequate SARS-CoV-2

anti-spike antibody after receiving the BNT162b2 vaccine. They were healthy and did

not have risk factors such as an organ transplant and immunosuppression. One possible

reason for this discrepancy is the different mechanism of antibody production between

conventional vaccines and SARS-CoV-2 mRNA vaccines.

The BNT162b2 vaccine is an mRNA vaccine, which incorporates mRNA

encoding spike protein (antigen) on the surface of the SARS-CoV-2 into human cells.

The produced antigen directly functions as a template to induce the acquired immune

system [27]. On the other hand, with live attenuated vaccines or inactivated vaccines, it

is necessary for recipients to process the vaccine and recognize it as an antigen. The

difference in the mechanism of action of vaccines could be a factor contributing to the

discrepancy in response to the BNT162b2 vaccine from the response to conventional

live attenuated vaccines among low responders. Such hypothesis should be tested in

future studies. It is also unclear why low responders had higher antibody titers than

normal responders in the first week after the second dose of vaccine.

Of note, the SARS-CoV-2 anti-spike antibody level is known to peak and then

decrease within months after the second vaccination, which is a much shorter period

than that of antibodies against live attenuated vaccines [28,29]. In order to achieve

adequate COVID-19 disease control, a third dose of SARS-CoV-2 mRNA vaccine is

needed, which is already being administered in many countries. In view of the results of

the present study, a third dose of the BNT162b2 vaccine should be recommended to

both low and normal responders to conventional vaccines. [28]

This study has some limitations. The number of participants was limited, and

all participants were HCWs vaccinated at a single hospital. In addition, there were no

low responders to inactivated vaccines (such as hepatitis B) included in this study.

Multicenter studies with a larger sample size are needed to confirm the results of the

present study. In addition, further immunological studies will be necessary to clarify the

mechanism by which humoral immunity is acquired after mRNA vaccination in low

responders to conventional vaccines.

In conclusion, after two doses of the BNT162b2 vaccine, low responders to

conventional antiviral vaccines developed protective levels of SARS-CoV-2 anti-spike

and SARS-CoV-2 neutralizing antibodies. These results suggest that vaccination with

mRNA vaccine against SARS-CoV-2 should also be recommended to low responders

against conventional vaccines.

Acknowledgments

We thank the HCWs of the Department of Clinical Laboratory, Kyorin

University Hospital involved in the SARS-CoV-2 antibody monitoring for their valuable

contribution.

References

1.   Coronaviridae Study Group of the International Committee on Taxonomy of

282   Viruses, Baker SC, Baric RS, de Groot RJ, Drosten C, et al. The species severe

283   acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and

284   naming it SARS-CoV-2. Nat Microbiol. 2020;5: 536-544. doi: 10.1038/s41564-

285   020-0695-z.

2.   Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus

associated with human respiratory disease in China. Nature. 2020;579: 265-269.

doi: 10.1038/s41586-020-2008-3.

3.   Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia

outbreak associated with a new coronavirus of probable bat origin. Nature.

2020;579: 270-273. doi: 10.1038/s41586-020-2012-7.

4.   Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from

patients with pneumonia in China, 2019. N Engl J Med. 2020;382: 727-733. doi:

10.1056/NEJMoa2001017.

5.   Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS,

Thrusting coronaviruses into the spotlight. Viruses. 2019;11: 59. doi:

10.3390/v11010059.

6.   Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et

al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a

clinically proven protease inhibitor. Cell. 2020;181: 271-280.e8. doi:

10.1016/j.cell.2020.02.052.

7.   Jiang S, Lu L, Liu Q, Xu W, Du L. Receptor-binding domains of spike proteins of

emerging or re-emerging viruses as targets for development of antiviral vaccines.

Emerg Microbes Infect. 2012;1: e13. doi: 10.1038/emi.2012.1.

8.   Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact

and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections

and COVID-19 cases, hospitalisations, and deaths following a nationwide

vaccination campaign in Israel: an observational study using national surveillance

data. Lancet. 2021;397: 1819-1829. doi: 10.1016/S0140-6736(21)00947-8.

9.   Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety

and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med.

2020;383: 2603-2615. doi: 10.1056/NEJMoa2034577.

10.   Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2

mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med.

2021;384: 1412-1423. doi: 10.1056/NEJMoa2101765.

11.   Regev-Yochay G, Amit S, Bergwerk M, Lipsitch M, Leshem E, Kahn R, et al.

Decreased infectivity following BNT162b2 vaccination: a prospective cohort

study in Israel. Lancet Reg Health Eur. 2021;7: 100150. doi:

10.1016/j.lanepe.2021.100150.

12.   Petter E, Mor O, Zuckerman N, Oz-Levi A, Younger A, Aran D, et al. Initial real

world evidence for lower viral load of individuals who have been vaccinated by

BNT162b2. Preprint; 2021. doi: 10.1101/2021.02.08.21251329.

13.   Pharmaceuticals and Medical Devices Agency. Special Approval for Emergency

on first COVID-19 vaccine in Japan [media release]. 2021. Available from:

pmda.go.jp. [Cited 2022 February 20] Available from:

https://www.pmda.go.jp/english/about-pmda/0003.pdf

14.   Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M.

Seroprevalence survey on measles, mumps, rubella and varicella antibodies in

healthcare workers in Japan: sex, age, occupational-related differences and

vaccine efficacy. Epidemiol Infect. Cambridge University Press. 2014;142: 12-19.

doi: 10.1017/S0950268813000393.

15.   Riester E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, et al.

Performance evaluation of the Roche Elecsys anti-SARS-CoV-2 S immunoassay.

J Virol Methods. 2021;297: 114271. doi: 10.1016/j.jviromet.2021.114271.

16.   Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Quantification of SARS-CoV-2

neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020;15:

3699-3715. doi: 10.1038/s41596-020-0394-5.

17.   McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al.

Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature.

2021;590: 630-634. doi: 10.1038/s41586-020-03041-6.

18.   Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for

medical statistics. Bone Marrow Transplant. 2013;48: 452-458. doi:

10.1038/bmt.2012.244.

19.   Muik A, Wallisch AK, Sänger B, Swanson KA, Mühl J, Chen W, et al.

Neutralization of SARS-CoV-2 lineage B.1.1.7 Pseudovirus by BNT162b2

vaccine-elicited human sera. Science. 2021;371: 1152-1153. doi:

10.1126/science.abg6105.

20.   Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586: 516-527.

doi: 10.1038/s41586-020-2798-3.

21.   Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine

vaccines: why and what to do? Hum Vaccin Immunother. 2016;12: 239-243. doi:

10.1080/21645515.2015.1093263.

22.   Shem-Tov N, Yerushalmi R, Danylesko I, Litachevsky V, Levy I, Olmer L, et al.

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in

haematopoietic stem cell transplantation recipients. Br J Haematol. 2022;196:

884-891. doi: 10.1111/bjh.17918.

23.   Nomura Y, Sawahata M, Nakamura Y, Kurihara M, Koike R, Katsube O, et al.

Age and smoking predict antibody titres at 3 months after the second dose of the

BNT162b2 COVID-19 vaccine. Vaccines (Basel). 2021;9: 1042. doi:

10.3390/vaccines9091042.

24.   Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L,

et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with

hematologic malignancies. Am J Hematol. 2021;96: 1195-1203. doi:

10.1002/ajh.26284.

25.   Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I,

Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the

COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a

prospective observational study. Lancet Oncol. 2021;22: 765-778. doi:

10.1016/S1470-2045(21)00213-8.

26.   Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al.

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in

adults with solid tumors. Nat Med. 2021;27: 2002-2011. doi: s41591-021-01542-z.

27.   Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the main anti-

SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug

Resist. 2021;14: 3459-3476. doi: 10.2147/IDR.S315727.

28.   Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A, et al.

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test

negative design study BMJ 2021; 375 :e067873 doi: org/10.1136/bmj-2021-

067873.

29.   Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning

immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl

J Med. 2021;385: e84-e84. doi: 10.1056/NEJMoa2114583.